Aplidin PharmaMar.

  • Lei Yao
  • Published 2003 in IDrugs : the investigational drugs journal

Abstract

Aplidin is a cell cycle inhibitor being developed by PharmaMar SA for the potential treatment of a variety of cancers, including non-Hodgkin's lymphoma (NHL), non-small-cell lung cancer (NSCLC), acute lymphoblastic leukemia (ALL), neuroendocrine, prostate, gastric and colorectal cancers [390131], [464778]. 

Topics

Cite this paper

@article{Yao2003AplidinP, title={Aplidin PharmaMar.}, author={Lei Yao}, journal={IDrugs : the investigational drugs journal}, year={2003}, volume={6 3}, pages={246-50} }